Neulasta (pegfilgrastim): a once-per-cycle option for the management of chemotherapy-induced neutropenia
- 1 June 2004
- journal article
- review article
- Published by Elsevier BV in Seminars in Oncology
- Vol. 31, 27-34
- https://doi.org/10.1053/j.seminoncol.2004.04.002
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Cost-benefit analysis of granulocyte colony-stimulating factor in the management of elderly cancer patientsCurrent Opinion in Hematology, 2002
- Colony-Stimulating Factors for the Management of Neutropenia in Cancer PatientsDrugs, 2002
- 2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice GuidelinesJournal of Clinical Oncology, 2000
- A Predictive Model for Neutropenia Associated with Cancer ChemotherapyPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2000
- Dose and Dose Intensity as Determinants of Outcome in the Adjuvant Treatment of Breast CancerJNCI Journal of the National Cancer Institute, 1998
- Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: results of a multivariate analysis.Journal of Clinical Oncology, 1998
- Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer — The Results of 20 Years of Follow-upNew England Journal of Medicine, 1995
- Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapyEuropean Journal of Cancer, 1993
- Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung CancerNew England Journal of Medicine, 1991
- Quantitative Relationships Between Circulating Leukocytes and Infection in Patients with Acute LeukemiaAnnals of Internal Medicine, 1966